Sedation and analgesia-prescribing patterns in terminally ill patients at the end of life

American Journal of Hospice and Palliative Medicine

Volumn 22, Issue 6, 2005, Pages 465-473

  Vitetta, Luis ^a   Kenner, David ^b,c   Sali, Avni ^d  

^a EPWORTH HOSPITAL   (Australia)

^b CABRINI HOSPITAL   (Australia)

^c BOX HILL HOSPITAL   (Australia)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Analgesia; End of life; Palliative care; Sedation; Terminal

Indexed keywords

EID: 28444473550     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910502200601     Document Type: Review

References (35)

1. Higginson IJ, Hearn J: A multicenter evaluation of cancer pain control by palliative care teams. J Pain Symptom Manage. 1997; 14(1): 29-35.
2. Swanwick M, Haworth M, Lennard RF: The prevalence of episodic pain in cancer: A survey of hospice patients on admission. Palliat Med. 2001; 15(1): 9-18.
3. Portenoy RK: Epidemiology and syndromes of cancer pain. Cancer. 1989; 63: 2298-2307.
4. Ventafrida V, Ripamonti C, De Conno F, et al.: Symptom prevalence and control during cancer patents' last days of life. J Palliat Care. 1990; 6: 7-11.
5. Vainio A, Auvinen A: Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage. 1996; 12(1): 3-10.
6. Lichter I, Hunt E: The last 48 hours of life. J Palliat Care. 1990; 6: 7-15.
7. Chater S, Viola R, Paterson PL, et al.: Sedation for intractable distress in the dying - a survey of experts. Palliat Med. 1998; 12: 255-269.
8. Muller-Busch HC, Andres I, Jehser T: Sedation in palliative care: Acritical analysis of 7 years experience. BMC Palliat Care. 2003; 2(1): 2.
9. Morita T, Tsuneto S, Shima Y: Determination of sedation for symptom relief: A systematic literature review and a proposal of operational criteria. J Pain Symptom Manage. 2002; 24(4): 447-453.
10. Cowan JD, Walsh D: Terminal sedation in palliative medicine: Definition and review of the literature. Support Cancer Care. 2001; 9: 403-407.
11. Broeckaert B, Nunez Olarte JM: Sedation in palliative care: Facts and concepts. In Have H, Clark D (eds.): The Ethics of Palliative Care: European Perspectives. Buckingham, UK: Open University Press, 2002: pp. 166-180.
12. Vitetta L, Kenner D, Kissane D, et al.: Clinical outcomes in terminally ill patients admitted to hospice care: Diagnostic and therapeutic interventions. J Palliative Care. 2001; 17(2): 67-75.
13. Vitetta L, Kenner D, Sali A: Bacterial infections in terminally ill hospice patients. J Pain Symptom Manage. 2000; 20: 326-334.
14. Twycross RG: The therapeutic equivalence of oral and subcutaneous/ intramuscular morphine sulphate in cancer patients. J Palliat Care. 1988; 4: 67-68.
15. Hanks GW, Conno F, Cherney N, et al.: Morphine and alternative opioids in cancer pain: The EAPC recommendations. Brit J Cancer. 2001; 84(5): 587-593.
16. Hanks GW, Hoskin PJ, Aherne GW, et al.: Explanation for potency of oral morphine on repeated dosage? Lancet. 1987; 2: 723-725.
17. Mercadante S, Bianchi M, Villari P, et al.: Opioid plasma concentration during switching from morphine to methadone: preliminary data. Support Care Cancer. 2003; 11(5): 326-331.
18. Cherny N, Ripamonti C, Pereira J, et al.: Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001; 19(9): 2542-2554.
19. McNamara P: Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliat Med. 2002; 16(5): 425-434.
20. Mercadante S, Casuccio A, Fulfaro F, et al.: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol. 200; 19(11): 2898-2904.
21. Mercadante S, Radbruch L, Caraceni A, et al.: Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94(3): 832-839.
22. Hanks GW, Portenoy RK, MacDonald N: Difficult pain problems. In Doyle D, Hanks GW, MacDonald N (eds.): Oxford Textbook of Palliative Medicine. Oxford, UK: Oxford University Press, 1993: pp. 257-274.
23. Dickerson D: The 20 essential drugs in palliative care. Eur J Palliat Care. 1999; 6: 130-135.
24. Vella-Brincat J, Macleod AD: Haloperidol in palliative care. Palliat Med. 2004; 18: 195-201.
25. LaPorte Matzo M, Witt Sherman D (eds.): Palliative Care Nursing: Quality Care to the End of Life. New York: Springer, 2001.
26. Burns JP, Mitchell C, Outwater KM, et al.: End-of-life care in the pediatric intensive care unit after the forgoing of life-sustaining treatment. Crit Care Med. 2000; 28(8): 3060-3066.
27. Holzapfel L, Demingeon G, Piralla B, et al.: A four-step protocol for limitation of treatment in terminal care. An observational study in 475 intensive care unit patients. Intensive Care Med. 2002; 28(9): 1309-1315.
28. O'Connor M, Aranda S (eds.): Palliative Care Nursing: A Guide to Practice (2nd ed.). Baltimore: Health Professions Press, 2003.
29. Sheehan DK, Schirm V: End-of-life care of older adults. Am J Nurs. 2003; 103(11): 48-51.
30. Breitbart W, Strout D: Delirium in the terminally ill. Clin Geriatr Med. 2000; 16(2): 357-372.
31. Breitbart W, Tremblay A, Gibson C: An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002; 43(3): 175-182.
32. Alexopoulos GS, Streim J, Carpenter D, et al.: Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65(suppl2): 5-99.
33. Skrobik YK, Bergeron N, Dumont M, et al.: Olanzapine vs haloperidol: Treating delirium in a critical care setting. Intensive Care Med. 2004; 30(3): 444-449.
34. Schwartz TL, Masand PS: The role of atypical antipsychotics in the treatment of delirium. Psychosomatics. 2002; 43(3): 171-174.
35. Sykes N, Thorns A: Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med. 2003; 163(3): 341-344.